BDGENE Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series C

  • Investors
  • 13

BDGENE General Information

Description

Developer of gene therapy drugs designed to cure eye diseases. The company offers gene editing, oncolytic virus platforms, lentiviral vectors, and gene delivery tools, enabling ophthalmologists to treat diabetic macular degeneration, age-related macular degeneration, and herpes simplex keratitis with improved precision and efficacy.

Contact Information

Website
www.bdgenetherapeutics.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Building 10, Number 55 Bixi Road
  • Minhang District
  • Shanghai, 200240
  • China
+86 177
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Building 10, Number 55 Bixi Road
  • Minhang District
  • Shanghai, 200240
  • China
+86 177

BDGENE Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BDGENE Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series C) 01-Apr-2026 Completed Generating Revenue
5. Later Stage VC (Series B1) 12-Nov-2023 Completed Generating Revenue
4. Early Stage VC (Series B) 01-May-2023 Completed Clinical Trials - General
3. Early Stage VC (Series A) 01-Mar-2021 Completed Clinical Trials - General
2. Early Stage VC 08-Mar-2020 $1.72M $1.72M Completed Pre-Clinical Trials
1. Corporate 25-Jun-2019 Completed Pre-Clinical Trials
To view BDGENE’s complete valuation and funding history, request access »

BDGENE Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
Hangzhou Hongcheng Capital Growth/Expansion Minority
Penglai Capital Venture Capital Minority
Shenzhen Yifeng Investment Management Enterprise Venture Capital Minority
Hermed Capital Venture Capital Minority
Lapam Capital Venture Capital Minority
You’re viewing 5 of 13 investors. Get the full list »

Ready to get started?

Request a free trial

BDGENE FAQs

  • When was BDGENE founded?

    BDGENE was founded in 2018.

  • Where is BDGENE headquartered?

    BDGENE is headquartered in Shanghai, China.

  • What industry is BDGENE in?

    BDGENE’s primary industry is Drug Discovery.

  • Is BDGENE a private or public company?

    BDGENE is a Private company.

  • What is BDGENE’s current revenue?

    The current revenue for BDGENE is .

  • How much funding has BDGENE raised over time?

    BDGENE has raised $40M.

  • Who are BDGENE’s investors?

    Hangzhou Hongcheng Capital, Penglai Capital, Shenzhen Yifeng Investment Management Enterprise, Hermed Capital, and Lapam Capital are 5 of 13 investors who have invested in BDGENE.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process